Navigation Links
Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure
Date:5/3/2011

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Researchers from the University of Cincinnati presented results from a prospective study at the American Roentgen Ray Society 2011 Annual Meeting today, demonstrating how PEM-guided biopsy may expedite pre-operative work-up and reduce radiation exposure for breast cancer patients.  

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment.  Naviscan's Stereo Navigator® Accessory is the first ever commercialized PET-guided biopsy tool and has been FDA-cleared since 2008.

"PEM is useful for performing local staging in women with newly diagnosed breast cancer," stated Dr. Amy Argus, Assistant Professor of Radiology and one of the lead investigators of the study. "When additional breast abnormalities are identified by PEM, accurate PEM-guided biopsy can be performed on the same day as the diagnostic imaging, which decreases the patient's radiation dose and may expedite their preoperative work-up."

In this study, 18 women with breast cancer classified as BIRADS 5 identified on mammography or ultrasound underwent a PEM scan and same day PEM-guided biopsy on 24 index and satellite lesions.  Lesion size was 4-60 mm with a mean size of 16 mm.  Results were concordant for 83% of lesions and discordant for the remaining due to patient movement and operator experience.  PEM is the only technology where physicians are able to biopsy on the same injection of the radiotracer.  This is because the radiotracer utilized, FDG, does not washout of the tumor as with other blood flow-dependant modalities like MRI or BSGI.  By avoiding a double injection of radiotracer, the radiation exposure to the patient and medical personnel is reduced.  Same day procedures are also feasible with PEM given the ease of interpretation compared to other advanced imaging modalities.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
2. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
3. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
4. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
5. Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
6. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. New Study Finds Individuals Who Adhere to Their Diabetes Medication Have a 31% Associated Lower Risk of Hospitalization
9. For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
10. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
11. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... 2017  Noble Capital Markets announced today that it ... EPIX ). The report was issued by ... PhD. ESSA Pharmaceuticals is a clinical stage ... (CRPC). Its lead compound EPI-506, is a small molecule ... the androgen receptor, thereby has potential to overcome some ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Sulphur Springs, Texas (PRWEB) , ... February 17, ... ... Electronic Signature 8.0 at the HIMSS17 Conference & Exhibition in Orlando, Fla., February ... the latest version of the most widely used electronic patient signatures solution ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... their Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 ... Staffing 100 honors those who have made notable contributions to the staffing industry ...
Breaking Medicine News(10 mins):